Chemoinformaics analysis of 2H-Pyran-2-one, tetrahydro-6-tridecyl-
| Molecular Weight | 282.468 | nRot | 12 |
| Heavy Atom Molecular Weight | 248.196 | nRig | 7 |
| Exact Molecular Weight | 282.256 | nRing | 1 |
| Solubility: LogS | -6.591 | nHRing | 1 |
| Solubility: LogP | 6.789 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 54 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 20 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 34 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 18 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 54.335 |
| nHD | 0 | BPOL | 36.713 |
| QED | 0.335 |
| Synth | 2.572 |
| Natural Product Likeliness | 1.118 |
| NR-PPAR-gamma | 0.912 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.019 |
| Pgp-sub | 0.001 |
| HIA | 0.003 |
| CACO-2 | -4.775 |
| MDCK | 0.0000251 |
| BBB | 0.14 |
| PPB | 0.973273 |
| VDSS | 1.801 |
| FU | 0.0184565 |
| CYP1A2-inh | 0.243 |
| CYP1A2-sub | 0.195 |
| CYP2c19-inh | 0.362 |
| CYP2c19-sub | 0.062 |
| CYP2c9-inh | 0.156 |
| CYP2c9-sub | 0.949 |
| CYP2d6-inh | 0.235 |
| CYP2d6-sub | 0.092 |
| CYP3a4-inh | 0.511 |
| CYP3a4-sub | 0.099 |
| CL | 4.604 |
| T12 | 0.224 |
| hERG | 0.144 |
| Ames | 0.005 |
| ROA | 0.007 |
| SkinSen | 0.963 |
| Carcinogencity | 0.102 |
| EI | 0.918 |
| Respiratory | 0.822 |
| NR-Aromatase | 0.092 |
| Antiviral | Yes |
| Prediction | 0.613013 |